| Bioactivity | Ogalvibart (C-135-LS) is a humanized anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model[1]. |
| Target | SARS-CoV-2. |
| In Vivo | Ogalvibart (C-135-LS; 10 mg/kg; 75 days before infection) in combination with 10 mg/kg C144LS can effectively block development of COVID-19 in the rhesus disease model[1]. Animal Model: |
| Name | Ogalvibart |
| CAS | 2599039-60-6 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Beddingfield BJ, et al. Effective Prophylaxis of COVID-19 in Rhesus Macaques Using a Combination of Two Parenterally-Administered SARS-CoV-2 Neutralizing Antibodies. Front Cell Infect Microbiol. 2021 Nov 18;11:753444. |